Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New vaccine could prevent condition that causes 500,000 infant deaths a year worldwide

05.01.2006


In a new study of more than 68,000 infants published in this week’s New England Journal of Medicine, the investigational vaccine Rotateq demonstrated that it can safely prevent 98 percent of severe cases of viral diarrhea and vomiting that account for 2 million hospital visits and 500,000 pediatric deaths each year worldwide.



In one of the largest pre-licensure vaccine clinical trials ever conducted worldwide, research championed by an Eastern Virginia Medical School investigator demonstrated that the oral vaccine Rotateq virtually eliminated the most severe cases of rotavirus, a common childhood virus that sometimes becomes deadly.

“This is good news for children everywhere,” said principal investigator David O. Matson, M.D., professor of pediatrics at Eastern Virginia Medical School (EVMS) and head of infectious diseases at EVMS’ Center for Pediatric Research. “In a matter of hours, vomiting and diarrhea from rotavirus can lead to dehydration, which can result in hospitalization and even be life-threatening.”


Rotavirus causes about 70,000 hospital admissions in the United States annually, or about five percent of all pediatric admissions. It also results in 250,000 visits each year to U.S. emergency rooms.

In the developing world, where prompt hospitalization and effective treatment may not be available, rotavirus kills half a million infants a year, about one child each minute. Matson, widely regarded as one of the nation’s leading rotavirus researchers, has studied the virus for over two decades.

“Development of a safe and effective rotavirus vaccine has been a worldwide priority since the virus was discovered in the 1970s,” Matson said. “It became clear at that time that it was one of the major killers of children, and there was no effective treatment.”

Rotavirus is endemic and infections occur in almost all children. The severity of rotavirus infection ranges from no symptoms to dehydrating gastroenteritis that can be fatal.

Efforts to eradicate rotavirus disease were almost derailed in 1999 when another vaccine was pulled from the market because it caused a rare bowel obstruction called intussusception at a rate of one in 10,000 patients. Intussusception takes place when the bowel folds in on itself, causing an intestinal blockage.

Because the bowel obstruction was so rare, and the increased incidence was so small, the only way to evaluate the safety of a new rotavirus vaccine was to launch a clinical trial involving more than 60,000 infants.

In 2000, Merck asked Matson to serve as the U.S. principal investigator in a clinical trial of RotaTeq, a vaccine under development.

RotaTeq targets five major strains of rotavirus, which account for 90 percent of rotavirus disease. The trial involved infants in the United States, Belgium, Costa Rica, Finland, Germany, Guatemala, Italy, Jamaica, Mexico, Sweden and Taiwan.

Infants were randomly assigned to receive three doses of vaccine or placebo, given four to 10 weeks apart. Because of the bowel obstruction associated with the withdrawn vaccine, a primary goal of the study was to determine whether RotaTeq was safe. Overall, 68,038 infants between six and 12 weeks participated, 34,035 in the vaccine group and 34,003 in the placebo group. All were monitored for serious adverse events, including intussusception.

During the study, infants who received the vaccine actually had a lower incidence of intussusception: 12 cases among vaccine recipients and 15 among those who received a placebo. No other significant side effects or complications were reported.

Rotateq also proved to be effective, nearly eliminating serious rotavirus-related gastroenteritis. The vaccine reduced rotavirus-related hospital admissions by 96 percent. In addition, RotaTeq reduced rotavirus-related emergency rooms visits by 94 percent, and doctor’s office visits by 86 percent.

“The protective effect is strongest against the most severe disease,” Matson said.

RotaTeq is presently under review by the U.S. Food and Drug Administration (FDA). Merck has filed for licensure of RotaTeq in 50 other countries and plans to evaluate the use of RotaTeq in the developing world.

The Merck study appeared in the same issue of the New England Journal of Medicine as a study of a rotavirus vaccine developed by GlaxoSmithKline. An accompanying editorial underscores the need for a rotavirus vaccine.

Doug Gardner | EurekAlert!
Further information:
http://www.evms.edu
http://www.gsk.com

More articles from Studies and Analyses:

nachricht Rutgers-led innovation could spur faster, cheaper, nano-based manufacturing
14.02.2018 | Rutgers University

nachricht New study from the University of Halle: How climate change alters plant growth
12.01.2018 | Martin-Luther-Universität Halle-Wittenberg

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

Im Focus: Autonomous 3D scanner supports individual manufacturing processes

Let’s say the armrest is broken in your vintage car. As things stand, you would need a lot of luck and persistence to find the right spare part. But in the world of Industrie 4.0 and production with batch sizes of one, you can simply scan the armrest and print it out. This is made possible by the first ever 3D scanner capable of working autonomously and in real time. The autonomous scanning system will be on display at the Hannover Messe Preview on February 6 and at the Hannover Messe proper from April 23 to 27, 2018 (Hall 6, Booth A30).

Part of the charm of vintage cars is that they stopped making them long ago, so it is special when you do see one out on the roads. If something breaks or...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Fingerprints of quantum entanglement

16.02.2018 | Information Technology

'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers

16.02.2018 | Health and Medicine

Hubble sees Neptune's mysterious shrinking storm

16.02.2018 | Physics and Astronomy

VideoLinks
Science & Research
Overview of more VideoLinks >>>